| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sara Gianella | Q90282543 |
| P2093 | author name string | Douglas D Richman | |
| P2860 | cites work | Mutations of Bacteria from Virus Sensitivity to Virus Resistance | Q24533278 |
| Genome sequencing in microfabricated high-density picolitre reactors | Q24544260 | ||
| Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS) | Q24635921 | ||
| Mutation rates among RNA viruses | Q24643023 | ||
| High-throughput genotyping of single nucleotide polymorphisms with rolling circle amplification | Q24802380 | ||
| HIV drug resistance acquired through superinfection | Q28264308 | ||
| Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy | Q28367526 | ||
| Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations | Q28469253 | ||
| Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study | Q28472889 | ||
| Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy | Q28473296 | ||
| Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use | Q28475651 | ||
| HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time | Q29547822 | ||
| Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy | Q29615992 | ||
| Recovery of replication-competent HIV despite prolonged suppression of plasma viremia | Q29615995 | ||
| Rates of evolutionary change in viruses: patterns and determinants | Q29616174 | ||
| HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy | Q29616404 | ||
| Analysis of heterogeneous viral populations by direct DNA sequencing | Q72908388 | ||
| The clinical significance of the emergence of drug-resistant organisms during the therapy of chronic pulmonary tuberculosis with hydrazides of isonicotinic acid | Q73162025 | ||
| Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine | Q73464171 | ||
| Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy | Q74372663 | ||
| Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine | Q80713101 | ||
| Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load | Q83203659 | ||
| Increased detection of HIV-1 drug resistance at time of diagnosis by testing viral DNA with a sensitive assay | Q83738271 | ||
| Clade B HIV-1 superinfection with wild-type virus after primary infection with drug-resistant clade B virus | Q45724887 | ||
| Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team | Q45754372 | ||
| Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. | Q45773659 | ||
| Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates | Q45789356 | ||
| Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. | Q45990014 | ||
| Persistence of primary drug resistance among recently HIV-1 infected adults | Q46048921 | ||
| Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients | Q46195814 | ||
| Antiretroviral-drug resistance among patients recently infected with HIV. | Q46277555 | ||
| A Ligase-Mediated Gene Detection Technique | Q46414808 | ||
| Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. | Q46490057 | ||
| Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. | Q46491049 | ||
| Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. | Q46534172 | ||
| Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. | Q46806431 | ||
| Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. | Q46964850 | ||
| Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors | Q46971468 | ||
| Characterization of minority subpopulations in the mutant spectrum of HIV-1 quasispecies by successive specific amplifications. | Q48078122 | ||
| Massively parallel signature sequencing profiling of fetal human neural precursor cells. | Q48562480 | ||
| Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. | Q50139327 | ||
| Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates. | Q51321707 | ||
| LigAmp for sensitive detection of single-nucleotide differences. | Q53863271 | ||
| Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. | Q53890023 | ||
| Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assay. | Q53976104 | ||
| Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. | Q53978434 | ||
| Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. | Q54029097 | ||
| Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. | Q54525316 | ||
| Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo. | Q54563531 | ||
| Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. | Q54622397 | ||
| Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. | Q54635976 | ||
| No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs | Q56778301 | ||
| Sensitive detection of the K103N non-nucleoside reverse transcriptase inhibitor resistance mutation in treatment-naïve HIV-1 infected individuals by rolling circle amplification | Q57076519 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase | Q29619994 | ||
| Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy | Q33565604 | ||
| Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis | Q33592278 | ||
| Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors | Q33601530 | ||
| Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy | Q33605273 | ||
| Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure | Q33672541 | ||
| Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients | Q33714377 | ||
| Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission | Q33739249 | ||
| Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection | Q33825654 | ||
| Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. | Q33843040 | ||
| Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. | Q33938281 | ||
| Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing | Q33971117 | ||
| A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 | Q33979107 | ||
| Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase | Q34066537 | ||
| Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants | Q34143613 | ||
| Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations | Q34331628 | ||
| Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy | Q34332659 | ||
| Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. | Q34357238 | ||
| Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated | Q34424673 | ||
| Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors | Q34454630 | ||
| A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics | Q34588592 | ||
| Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission | Q34598577 | ||
| Single-well genotyping of diallelic sequence variations by a two-color ELISA-based oligonucleotide ligation assay | Q34612760 | ||
| Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency | Q34719734 | ||
| Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy | Q34786892 | ||
| Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection | Q35104695 | ||
| Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene | Q35132164 | ||
| Combined drug treatment of tuberculosis. I. Prevention of emergence of mutant populations of tubercle bacilli resistant to both streptomycin and isoniazid in vitro | Q35572904 | ||
| Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism | Q35635933 | ||
| Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy | Q35828466 | ||
| Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients | Q35872364 | ||
| Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance | Q35914785 | ||
| Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies | Q35947480 | ||
| Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. | Q36673315 | ||
| Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase | Q36810415 | ||
| Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations. | Q36949610 | ||
| Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants | Q36973809 | ||
| Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. | Q37093847 | ||
| Implications of recombination for HIV diversity | Q37097501 | ||
| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection | Q37273158 | ||
| The remarkable frequency of human immunodeficiency virus type 1 genetic recombination | Q37333701 | ||
| Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine | Q37351372 | ||
| Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission | Q37396569 | ||
| Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. | Q37574543 | ||
| Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. | Q37621435 | ||
| Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains | Q37743275 | ||
| HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time | Q38438607 | ||
| The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy | Q38470650 | ||
| Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. | Q38879379 | ||
| Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns | Q38880191 | ||
| Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211 | Q39495730 | ||
| Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy | Q39562375 | ||
| Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population | Q39642550 | ||
| Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults | Q39685276 | ||
| Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management | Q40396257 | ||
| Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy | Q40782728 | ||
| Response to antiretroviral therapy after a single, peripartum dose of nevirapine | Q40799526 | ||
| Viral quasispecies. | Q40828271 | ||
| Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay | Q40909665 | ||
| Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes | Q41698277 | ||
| Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy | Q43145005 | ||
| Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. | Q43153472 | ||
| Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy | Q43271726 | ||
| Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. | Q43863293 | ||
| Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes | Q43889383 | ||
| Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions | Q43937452 | ||
| Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. | Q44043469 | ||
| Transmission of drug-resistant HIV-1 is stabilizing in Europe | Q44591236 | ||
| Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure | Q44609770 | ||
| Detection of drug-resistant HIV minorities in clinical specimens and therapy failure | Q44750837 | ||
| The frequency of resistant mutant virus before antiviral therapy | Q44753747 | ||
| Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine | Q44785809 | ||
| Nucleic acid analysis using an expanded genetic alphabet to quench fluorescence. | Q44834647 | ||
| Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations. | Q45004725 | ||
| Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine | Q45193916 | ||
| Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. | Q45285923 | ||
| Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure | Q45296112 | ||
| Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions | Q45709309 | ||
| Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus | Q45722048 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 657-666 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Minority variants of drug-resistant HIV. | |
| P478 | volume | 202 |
| Q30410899 | Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives |
| Q42704311 | Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance |
| Q28541754 | Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy |
| Q30241725 | Deep sequencing for HIV-1 clinical management |
| Q36817632 | Detection of HIV-1 minority variants containing the K103N drug-resistance mutation using a simple method to amplify RNA targets (SMART). |
| Q35140450 | Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. |
| Q28481233 | Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission |
| Q42577298 | Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecks |
| Q35582579 | Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses |
| Q26864534 | HIV Drug Resistance: Problems and Perspectives |
| Q37519808 | HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission |
| Q57207278 | HIV-1 Drug Resistance in Pre-exposure Prophylaxis Trials |
| Q28649612 | How bioinformatics influences health informatics: usage of biomolecular sequences, expression profiles and automated microscopic image analyses for clinical needs and public health |
| Q36904981 | Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents |
| Q35275215 | Human leukocyte antigen genotype and risk of HIV disease progression before and after initiation of antiretroviral therapy |
| Q26851997 | Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomes |
| Q42277198 | Improved detection of mutated human cytomegalovirus UL97 by pyrosequencing |
| Q36933330 | Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. |
| Q35887051 | Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis |
| Q37582339 | Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP. |
| Q36060517 | Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment |
| Q93078822 | MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors |
| Q28478779 | Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure |
| Q28534497 | Molecular characterization of ambiguous mutations in HIV-1 polymerase gene: implications for monitoring HIV infection status and drug resistance |
| Q36240649 | One-Step Ligation on RNA Amplification for the Detection of Point Mutations |
| Q42255433 | Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection |
| Q37336600 | Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible? |
| Q36507279 | Quantifying Next Generation Sequencing Sample Pre-Processing Bias in HIV-1 Complete Genome Sequencing |
| Q28478934 | Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection |
| Q28076177 | Recent advances in inferring viral diversity from high-throughput sequencing data |
| Q28728617 | Routine use of microbial whole genome sequencing in diagnostic and public health microbiology |
| Q34853625 | Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy |
| Q33622927 | Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. |
| Q46499496 | Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries |
| Q28484153 | Standing genetic variation and the evolution of drug resistance in HIV |
| Q57470348 | Surveillance of transmitted HIV-1 antiretroviral drug resistance in the context of decentralized HIV care in Senegal and the Ebola outbreak in Guinea |
| Q36641998 | Towards Better Precision Medicine: PacBio Single-Molecule Long Reads Resolve the Interpretation of HIV Drug Resistant Mutation Profiles at Explicit Quasispecies (Haplotype) Level |
| Q41758916 | VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering |
| Q38215850 | When can HIV clinical trials detect treatment effects on drug resistance? |
Search more.